Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JPC0323
- Development stage
- Preclinical
- Lead developer
- The University of Texas Medical Branch at Galveston
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Oral
01
Overview
JPC0323 is a first-in-class, brain-penetrant dual positive allosteric modulator (PAM) of the serotonin 5-HT2A and 5-HT2C receptors. Derived as an analogue of the fatty acid amide oleamide, JPC0323 selectively enhances 5-HT-evoked calcium efflux at both 5-HT2A and 5-HT2C receptors without displaying intrinsic agonist activity or affecting the 5-HT2B receptor. Developed by researchers at the University of Texas Medical Branch (UTMB), JPC0323 has demonstrated preclinical efficacy in reducing cocaine intake and reinstatement of cocaine-seeking behavior in rat models of cocaine use disorder, as well as suppressing novelty-induced locomotor activity.
- Other names
- N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)oleamideN-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-9Z-octadecenamidecompound 13compound13compound-13
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on JPC0323.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JPC0323.